Author pages are created from data sourced from our academic publisher partnerships and public sources.
Labile plasma iron in iron overload: redox activity and susceptibility to chelation.
- B. P. Espósito, W. Breuer, P. Sirankapracha, P. Pootrakul, C. Hershko, Z. I. Cabantchik
- 1 October 2003
Plasma non-transferrin-bound-iron (NTBI) is believed to be responsible for catalyzing the formation of reactive radicals in the circulation of iron overloaded subjects, resulting in accumulation of… Expand
Non‐Specific Serum Iron in Thalassaemia: an Abnormal Serum Iron Fraction of Potential Toxicity
- C. Hershko, G. Graham, G. Bates, E. Rachmilewitz
- British journal of haematology
- 1 October 1978
Summary. Iron binding in the sera of 35 patients with β thalassaemia major and intermedia was studied. In patients receiving regular blood transfusions since infancy transferrin was completely… Expand
The importance of non-transferrin bound iron in disorders of iron metabolism.
The concept of non-transferrin bound iron (NTBI) was introduced 22 years ago by Hershko et al. (Brit. J. Haematol. 40 (1978) 255). It stemmed from a suspicion that, in iron overloaded patients, the… Expand
Role of deferiprone in chelation therapy for transfusional iron overload.
Before 1987, iron chelation therapy for patients with thalassemia major and other refractory anemias requiring regular transfusions depended almost entirely on one drug, deferoxamine. The drug has… Expand
Role of iron in the potentiation of anthracycline cardiotoxicity: identification of heart cell mitochondria as a major site of iron-anthracycline interaction.
- G. Link, R. Tirosh, A. Pinson, C. Hershko
- Chemistry, Medicine
- The Journal of laboratory and clinical medicine
- 1 March 1996
The role of iron in anthracycline toxicity was studied in rats in vivo in intact animals and in vitro in heart cell cultures. In animals treated with 8 mg/kg doxorubicin, iron loading resulted in… Expand
Action of chelators in iron-loaded cardiac cells: Accessibility to intracellular labile iron and functional consequences.
Labile iron in hemosiderotic plasma and tissue are sources of iron toxicity. We compared the iron chelators deferoxamine, deferiprone, and deferasirox as scavengers of labile iron in plasma and… Expand
Ichthyosiform dermatosis with systemic lipidosis.
Two sisters and two unrelated patients with an ichthyosiform dermatosis resembling nonbullous ichthyosiform erythroderma were found to have lipid accumulations in the granulocytes of the peripheral… Expand
The assessment of serum nontransferrin-bound iron in chelation therapy and iron supplementation.
Nontransferrin-bound iron (NTBI) appears in the serum of individuals with iron overload and in a variety of other pathologic conditions. Because NTBI constitutes a labile form of iron, it might… Expand
Results of long‐term deferiprone (L1) therapy: a report by the International Study Group on Oral Iron Chelators
Summary This report updates the combined experience of four centres involved in the long‐term treatment of transfusional iron overload in 84 patients with the oral iron chelator deferiprone (L1) over… Expand
Desferrioxamine-chelatable iron, a component of serum non-transferrin-bound iron, used for assessing chelation therapy.
- W. Breuer, M. Ermers, P. Pootrakul, A. Abramov, C. Hershko, Z. I. Cabantchik
- 1 February 2001
This study introduces a method for monitoring a component of serum non-transferrin-bound iron (NTBI), termed "desferrioxamine-chelatable iron" (DCI). It is measured with the probe… Expand